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a. Major depressive disorder – a global health 
problem
Major depressive disorder (MDD) is a disabling psychiat‑
ric disorder, with the World Health Organization (WHO) 
estimating more than 300 million people are affected by 
this condition, and considering depression the single larg‑
est contributor to global disability, accounting for 10% of 
all years lived with disability.1 Unfortunately, approximate‑
ly one third of patients with MDD fail to respond to stan‑
dard treatment, a condition known as treatment resistant 
depression (TRD), with great impact on patients and their 
families. Furthermore, common antidepressants may take 
too long to reach sustained clinical efficacy and, even in 
responders, there are significant relapse rates, highlight‑
ing the need to explore innovative treatments. While new 
antidepressant strategies have been approved to alleviate 
patient suffering, including transcranial magnetic stimula‑
tion and esketamine, psychedelics have also been recently 
considered as potential therapeutic options for MDD. 
b. What are psychedelics?
Psychedelics are substances that temporarily induce an 
altered state of mind, variably described as a combination 
of dissociation, perceptual distortions and mystical experi‑
ence, among other effects. They act on the serotoninergic 
system, as 5 ‑hydroxytryptamine 2A (5 ‑HT2A) receptor 
agonists.2 The term psychedelic was first used by the psy‑
chiatrist Humphrey Osmond in 1956, derived from Greek 
to mean ‘mind manifesting’.3 Not surprisingly, since their 
discovery by the scientific community, psychedelics were 
widely used in psychiatry for clinical and research purpos‑
es, until their legal prohibition in the 1960s.3 Mescaline, 
dimethyltryptamine (DMT), lysergic acid diethylamide 
(LSD) and psilocybin are examples of psychedelics, the 
latter being the most promising for treatment of MDD.2 
Psilocybin is an indole alkaloid present in certain mush‑
room species, used by ancient cultures in religious rituals 
in order to induce a pleasant and positive spiritual/mystical 
experience.
c. Treating major depressive disorder with 
psilocybin
Prior to their prohibition, therapeutic use of psychedelics, 
including psilocybin, was mainly motivated by their ca‑
pacity to induce a “transformative experience” in patients 
diagnosed with then ‑called ‘neurotic’ disorders, leading to 
both short ‑ and long ‑term improvements of symptoms,2 in‑
cluding anxiety, depression and pain..3 However, following 
legal restrictions to their use, and despite the encouraging 
results obtained previously, psychedelics were ignored for 
more than two decades. Only recently has the scientific 
community revisited psilocybin, mainly motivated by the 
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need to develop new treatments options for depression. In 
2011, a small cross ‑over placebo ‑controlled trial, in a co‑
hort of 12 advanced ‑stage cancer patients, revealed trends 
towards reduction of depression and anxiety symptoms 
after psilocybin administration.4 More recently, two more 
robust double ‑blind cross ‑over trials, with 51 and 29 partic‑
ipants, provided evidence of the significant antidepressant 
and anxiolytic effects of psilocybin in patients with cancer, 
when compared to active placebo.4 Importantly, the effects 
reported in these three studies were immediate and sustained 
after psilocybin. In 2018, a first open ‑label study attempted 
to investigate feasibility, safety, and efficacy of psilocybin 
in TRD, with authors reporting no major adverse effects, 
while depressive symptoms markedly reduced at 1 week, 
3 months and 6 months after psilocybin.4 Noteworthy, the 
overall pre ‑post effect size in the reduction of depressive 
symptoms among the patients who received psilocybin 
was approximately 1.5, when considering the four afore‑
mentioned trials.4 More recently, Davis and colleagues, 
in a randomized waiting list ‑controlled study (n=27), fur‑
ther supported treatment efficacy and safety of psilocybin 
administration in patients diagnosed with MDD, with a 
remission rate larger than 50%,5 while Carhart ‑Harris and 
colleagues have shown that two doses of psilocybin were 
as effective as escitalopram.6
d. What are the mechanisms of action of 
psilocybin?
While there is increasing data regarding its clinical effica‑
cy, the antidepressant mechanisms of psilocybin are still 
unknown. It is known that psilocybin acts as serotonin 
agonist, producing effects on cognition, perception and 
emotion.2Specifically, it modifies cortical excitability and 
reactivity through 5HT ‑2A receptor agonism.2 Further‑
more, there is evidence that 5HT ‑2A agonism, is associated 
with neuroplastic phenomena such as increases of neuron 
branching and of the number and length of dendrites.7 
These findings are consistent with one of the most well 
accepted pathophysiological theories for MDD, namely 
the impairment of brain neuroplasticity, i.e., capacity to 
generate, maintain, migrate, and integrate neurons/neu‑
ronal activity. According to this theory, neuroplasticity is 
decreased in MDD, producing changes in behavior, cogni‑
tions and emotions that characterize this disorder. Psilocy‑
bin, through 5HT ‑2A agonism, may revert these processes, 
resulting in long ‑lasting antidepressant effects.7
At the brain network level, interesting but somewhat 
counterintuitive findings have been reported. After acute 
psilocybin administration in healthy individuals, the 
medial prefrontal cortex (mPFC) and anterior cingulate 
cortex (ACC) were less positively functionally connected 
to posterior cingulate cortex when compared to placebo, 
as shown in resting ‑state functional magnetic resonance 
imaging (rs ‑fMRI), while the cerebral blood flow (CBF) 
decreased, a finding that was associated with intensity of 
reported effects for psilocybin.8 However, in patients diag‑
nosed with TRD, after psilocybin administration, ventral 
mPFC was more functionally connected to inferior lateral 
parietal cortex, an effect that was predictive of treatment 
response at 5 ‑weeks, as was decreased functional connec‑
tivity between prefrontal cortex and para ‑hippocampus 
and decrease in amygdala CBF.9 Decreased activity in the 
amygdala, as well as the para ‑hippocampus, is consistent 
with previous findings in rs ‑fMRI and event ‑based fMRI 
studies after treatment with selective serotonin reuptake 
inhibitors. However, in similarly designed studies, psilo‑
cybin increased amygdala responses to emotional stimuli 
among patients with TRD.10 Interestingly, some have ar‑
gued that psilocybin may work as a reset mechanism at 
brain network level, supported by findings of disintegration 
of Default Mode Network, a canonical resting state brain 
network associated to consciousness, thought to underlie 
psychological effects of psychedelics described as “ego 
dissolution”. As claimed by the authors, such resetting 
process would subsequently enable resumption of normal 
functioning, ultimately leading to the ability to resolve 
negative stimuli.8 ‑10 This hypothesis has been supported by 
recent findings that reported changes in personality traits 
following psilocybin therapy, namely a decrease in neurot‑
icism and increase extraversion and openness. 
e. Future perspectives
Interest in psilocybin therapeutic effects, mainly for 
depression treatment, has grown. Research have been 
developed to clarify its pharmacological properties, 
neurobiological impact, psychological and behavioral ef‑
fects, and most importantly, its therapeutic antidepressant 
mechanisms.2 Recent studies highlight that psilocybin is 
a safe and potentially effective option for depression, but 
there is consensus that more robust and carefully designed 
randomized controlled studies are necessary in this field. 
In fact, the available evidence is mostly based in trials 
that were either open ‑label or had a cross ‑over or waiting‑
‑list controlled design, leading to possible confounders 
and bias. Furthermore, the follow ‑up periods were short, 
not allowing for conclusions about long ‑term efficacy, the 
dose that should be used is still unclear, and the need for 
concomitant psychotherapy is unresolved. Importantly, 
multi ‑center randomized control trials using psilocy‑
bin are being conducted in Europe, including Portugal, 
and North America, to answer some of these questions. 
Nevertheless, the encouraging results obtained to date, 
particularly if confirmed by current ongoing trials, will 
certainly drive the scientific and clinical communities, as 
well as policy makers, to further develop this important 
field of research.
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